StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Moderna's total debt was $591.00M at Jun 30, 2026. For fiscal 2025 it was $590.00M.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$590.00M–
FY2024Dec 31, 2024$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$591.00M–
Q1 FY2026Mar 31, 2026$590.00M–
Q4 FY2025Dec 31, 2025$590.00M–
Q4 FY2024Dec 31, 2024$0–

More Moderna figures

See a number that looks wrong?